Related Experiment Video

Updated: Aug 30, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.0K

Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway

Ruijing Feng1, Xin Wang1, Hongwei Chen1

  • 1Department of Obstetrics and Gynecology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, Hubei, China.

Current Cancer Drug Targets
|August 26, 2022
PubMed
Abstract

Insights

Downregulating PRKD2 enhances chemotherapy sensitivity in cervical cancer by activating the TP53/CDKN1A pathway, leading to cell cycle arrest and apoptosis. PRKD2 is a potential therapeutic target for overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemotherapy resistance is a major challenge in cervical cancer treatment.
  • Previous research linked PRKD2 mutations to chemotherapy resistance in cervical cancer patients.
  • The specific role of PRKD2 in cervical cancer drug resistance was previously unknown.

Purpose of the Study:

  • To elucidate the relationship between PRKD2 and cervical cancer chemotherapy resistance.
  • To investigate PRKD2's mechanism in mediating drug resistance.
  • To identify PRKD2 as a potential therapeutic target.

Main Methods:

  • Whole-exome sequencing (WES) of tumor tissues from cervical cancer patients.
  • Assessment of chemotherapy response by measuring tumor volume.
  • In vitro studies using SiHa and ME180 cells with PRKD2 knockdown (siPRKD2) to evaluate cell viability and apoptosis via qRT-PCR, Western blot, CCK8, and flow cytometry.
  • Analysis of chemotherapy sensitivity-related proteins and PRKD2, TP53, and CDKN1A expression via immunohistochemistry.

Main Results:

  • Elevated PRKD2 expression was observed in chemotherapy-resistant cervical cancer tissues.
  • PRKD2 knockdown significantly increased cervical cancer cell sensitivity to chemotherapy.
  • PRKD2 downregulation promoted G1 cell cycle arrest and apoptosis through the TP53/CDKN1A pathway.

Conclusions:

  • PRKD2 plays a crucial role in mediating chemotherapy resistance in cervical cancer.
  • Targeting PRKD2, potentially through its downregulation, can enhance chemotherapeutic efficacy.
  • PRKD2 represents a promising therapeutic target for improving cervical cancer treatment outcomes.
Keywords:
Cervical cancerPRKD2TP53/CDKN1A pathwaychemotherapy sensitivitydrug resistancewhole exome sequencing

More Related Videos

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.4K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
251
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K